Thrombotic microangiopathy due to thrombotic thrombocytopenia should be suspected in a patient with otherwise unexplained thrombocytopenia and anemia, even without fever, renal dysfunction or ...

This report describes a newborn who presented with hyperbilirubinemia and thrombocytopenia. The patient recovered after treatment with antibiotics, phototherapy, and a platelet transfusion. Analysis ...

We monitored the levels of various cytokines and chemokines, as well as an adhesion molecule and factors related to vascular endothelial damage, in three patients with thrombotic thrombocytopenic ...

Adzynma is a purified recombinant form of the ADAMTS13 protein designed to replace the missing or deficient ADAMTS13 enzyme. The Food and Drug Administration (FDA) has approved Adzynma for ...

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation. X. Long Zheng, MD, PhD: What is acquired TTP? TTP ...

The COVID-19 pandemic has prompted the rapid development and administration of various vaccines worldwide, with some reports linking these vaccines to immune thrombotic thrombocytopenic purpura (TTP).

Patients with acquired thrombotic thrombocytopenic purpura experienced a faster normalization of platelet count when treated with caplacizumab than placebo, according to results of a randomized phase ...

Please provide your email address to receive an email when new articles are posted on . In this video, Iberia Romina Sosa, MD, PhD, discusses the results of a study presented at ASH Annual Meeting and ...

Paris - September 3, 2018 - The European Commission has granted marketing authorization for Cablivi(TM) (caplacizumab) for the treatment of adults experiencing an episode of acquired thrombotic ...

Sanofi announced that the Food and Drug Administration (FDA) has approved Cablivi (caplacizumab-yhdp) for the treatment of adults with acquired thrombotic thrombocytopenic purpura (aTTP), in ...

Key Companies Covered in the Thrombotic Thrombocytopenic Purpura Research are Ablynx NV, Kaketsuken, Biogen Inc, Shire Plc, Lee’s Pharmaceutical Holdings Ltd, Omeros Corp and other key market players.

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...